PhD Scientific Days 2026

Poster Session 2.K - Mental Health Sciences

Role of Patients’ CYP3A Status in Clozapine Pharmacokinetics: Ongoing Longitudinal Cohort Study

Előadó neve

Dr. Tóth, Eleonóra

Neptune code

JK2J1V

Előadó munkahelye

Nyírő Gyula National Institute of Psychiatry and Addictions

Előadó telefonszáma

+36209959626

Előadó e-mail címe

toth.eleonora@phd.semmelweis.hu

Az előadás címe

Role of Patients’ CYP3A Status in Clozapine Pharmacokinetics: Ongoing Longitudinal Cohort Study

Szerző(k) neve és munkahelye

Eleonóra Tóth MD¹, Ferenc Fekete², Katalin Monostory, PhD, DSc², Gábor Csukly, MD, PhD³

1: National Institute of Psychiatry and Addictions, Nyírő Gyula Hospital, Budapest, Hungary
2: Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary
3: Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

Bemutatás módja

Poszter

Szekció

Poster Session 2.K - Mental Health Sciences

Language of the presentation

Hungarian

Preferred session

Mental Health Sciences

Összefoglaló szövege

Introduction
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia; however, considerable interindividual variability in plasma concentrations at identical doses complicates its clinical use. Since adverse effects are more closely associated with plasma concentration than dose itself, identifying factors determining clozapine plasma levels is essential for personalised treatment.
Aims
We aimed to investigate whether baseline CYP3A status can predict the optimal clozapine dose and subsequent steady-state plasma levels in patients with schizophrenia or schizoaffective disorder according to DSM-5 criteria.
Methods
We designed a prospective longitudinal cohort study including 80–100 clozapine-naive patients with schizophrenia or schizoaffective disorder. CYP status is assessed using combined genotyping and phenotyping methods, with particular focus on CYP3A4 and CYP3A5 genotyping and CYP3A4 expression analysis from leukocytes. Clozapine plasma levels are measured after at least two weeks of unchanged dosing. Clinical effectiveness, tolerability, and relevant demographic and non-genetic variables are also recorded.
Result
Patient recruitment is ongoing, and the study protocol has been further refined to improve data collection and follow-up procedures.
Conclusion
We hypothesise that pre-treatment CYP3A status may serve as a clinically useful biomarker for predicting steady-state clozapine concentrations and supporting personalised dose optimisation.
Funding
The study is funded within the research framework of Semmelweis University without external financial support.

University

Semmelweis University

Supervisor

Gábor Csukly, MD, PhD, Katalin Monostory, PhD, DSc

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9170

Start

19:24

End

19:27